Release kinetics of VEGF$_{165}$ from a collagen matrix and structural matrix changes in a circulation model

Johannes Kleinheinz* 1, Susanne Jung 1, Kai Wermker 1, Carsten Fischer 2 and Ulrich Joos 1

Abstract

**Background:** Current approaches in bone regeneration combine osteoconductive scaffolds with bioactive cytokines like BMP or VEGF. The idea of our *in-vitro* trial was to apply VEGF$_{165}$ in gradient concentrations to an equine collagen carrier and to study pharmacological and morphological characteristics of the complex in a circulation model.

**Methods:** Release kinetics of VEGF$_{165}$ complexed in different quantities in a collagen matrix were determined in a circulation model by quantifying protein concentration with ELISA over a period of 5 days. The structural changes of the collagen matrix were assessed with light microscopy, native scanning electron microscopy (SEM) as well as with immuno-gold-labelling technique in scanning and transmission electron microscopy (TEM).

**Results:** We established a biological half-life for VEGF$_{165}$ of 90 minutes. In a half-logarithmic presentation the VEGF$_{165}$ release showed a linear declining gradient; the release kinetics were not depending on VEGF$_{165}$ concentrations. After 12 hours VEGF release reached a plateau, after 48 hours VEGF$_{165}$ was no longer detectable in the complexes charged with lower doses, but still measurable in the 80 μg sample. At the beginning of the study a smear layer was visible on the surface of the complex. After the wash out of the protein in the first days the natural structure of the collagen appeared and did not change over the test period.

**Conclusions:** By defining the pharmacological and morphological profile of a cytokine collagen complex in a circulation model our data paves the way for further *in-vivo* studies where additional biological side effects will have to be considered. VEGF$_{165}$ linked to collagen fibrils shows its improved stability in direct electron microscopic imaging as well as in prolonged release from the matrix. Our *in-vitro* trial substantiates the position of cytokine collagen complexes as innovative and effective treatment tools in regenerative medicine and may initiate further clinical research.

Background

Osteogenesis

The human skeleton is subject to permanent remodelling processes: 5% of the human skeleton is rebuilt per year. This remodelling is an integral part also of the mechanism of bone healing and regeneration of bony defaults.

In the process of bone healing and regeneration, biochemical procedures follow a well-defined temporal and territorial pattern. Resting chondrocytes start to proliferate, differentiate into hypertrophic chondrocytes, and synthesise collagen and extracellular matrix.

Then blood vessels invade; osteogenesis takes place in the vicinity of neo-vessels that mediate the delivery of osteoprogenitors, secrete mitogen for osteoblasts, and transport nutrients and oxygen. The cartilage matrix is degraded and replaced with the typical trabecular bone matrix produced by osteoblasts. Blood vessels provide a conduit for the recruitment of cells involved in cartilage resorption and bone deposition and are therefore a crucial condition for any regeneration [1,2]. The process is operated by a variety of cytokines as bone morphogenetic proteins (BMPs) or vascular endothelial growth factor (VEGF) [3,4].
There are two basic options to support bone formation: to enhance the remodelling processes by optimizing the vascularization via application of potent angiogenetic cytokines as VEGF or to implant a scaffold to provide a matrix that induces bone regeneration [5,6].

VEGF165

VEGF is an important cytokine in the process of endothelial bone development and mediating bone vascularisation for normal differentiation of chondrocytes and osteoblasts. An increase in VEGF is an indication of increased vascular permeability and microvascular activity, including angiogenic growth of new blood vessels [7-9].

VEGF is a homodimer glycoprotein, its family includes 6 related proteins; VEGF165 is most common and biologically active [10]. It is released by many cell populations as fibroblasts, monocytes, macrophages or lymphocytes [11]. The corresponding receptors belong to the tyrosine kinase family. VEGF165 induces angiogenesis on different levels: it acts as mitogen especially on endothelial cells, raises the vessel permeability and dilatation by releasing NO and has chemotactic impact on other growth pro-
tection form, its short half-life and susceptibility to light and temperature.

Bone graft substitutes and collagen

Some of the common methods used to repair bony skeletal defects are autografts, allografts, or synthetic implant materials. Yet, imperfections persist in these methods, such as limited harvesting, the possibility of disease transmission, poor biocompatibility, and the risk of prosthetic implantation failure. Therefore, alternative strategies, such as tissue engineering approaches, are needed to improve the treatment and quality of life of all patients.

The minimum requirements for bone graft substitutes are:

- No cancerogenic effect
- No water-solubility
- Non-immunogenic effect
- Lacking of an inflammatory response

- Defined bio-degradation and
- Biocompatibility, namely of the surface.

Widely-used materials are hydroxylapatite and tricalcium phosphate as synthetic inorganic bone graft substitutes. They come with good biocompatibility and osteoconductivity. Yet, they are brittle and not resilient in functionally stressed areas [15-17]. The advantage of collagen as a natural substitute is the fact that collagen is the main constituent of organic bone matrix. Fitted in bony defaults it is not degraded by but incorporated into the regenerating tissue. It accelerates the healing process and reduces the side effects of decomposition products [18,19].

In innovative approaches the osteoconductive collagenous scaffold is combined with the osteoinductive impact of cytokines like BMP or VEGF165. The objectives of our study were to apply VEGF165 in gradient concentrations to an equine collagen carrier and to study the complex in a circulation model. The VEGF165 release kinetics should be quantified and the morphological degradation of the collagen-cytokine complex should be visualized.

Methods

VEGF165-collagen complex

Collagen I was purchased (Resorba, Nuernberg, Germany) and liquefied. Human recombinant VEGF165 (R&D Systems, Wiesbaden, Germany) was added in different concentrations. The complexes were formed in hemi-
spheres and drugged with aldehyde to avoid the cross-linking of collagen fibrils.

The total quantity of collagen was 5.6 mg/cm³ per application, VEGF165 was added in 0.8 μg, 10 μg or 80 μg quantities.

Circulation model

We used a digitally controlled peristaltic pump that deliv-
ered the medium with a mean flow rate of 27 ml per min-
ute (Cole Parmer Masterlex Console Drive Pump). As
aqueous solution a 0.2 mol PBS buffer was utilized in a total quantity of 80 ml. Circulation was simulated under constant conditions of 20°C and pH 7.2.

Lab report

The complexes were charged with VEGF165 in three differ-
ent concentrations: 0.8 μg, 10 μg and 80 μg. Three complexes of each concentration were incubated for 5 days. As a sample, the total volume of buffer medium was extracted and analysed to avoid saturation of the buffer medium with free VEGF165. To differentiate between the initial degradation of our collagen complexes with a quick VEGF165 release and the slow long-term saturation process, we adopted an asymmetrical test pattern:
On day one we took samples after 30 min, 1, 2, 4, 8, 12 and 24 hours. The next specimens were taken after day 2, 3, 4 and 5. VEGF<sub>165</sub>-free collagen complexes served as negative controls and were analysed identically.

**ELISA**
VEGF<sub>165</sub> concentrations were assessed by performing a solid-phase VEGF<sub>165</sub> Immunoassay (VEGF<sub>165</sub> Quantikine, DVE00, R&amp;D Systems GmbH, Wiesbaden-Nordenstadt, Germany). The ELISA was performed according to the manufacturer’s protocol; its sensitivity was described as < 9 pg/ml. The concentration of VEGF<sub>165</sub> was expressed as pg/ml.

VEGF<sub>165</sub> was quantified by using a standard curve made by human VEGF<sub>165</sub> ranging from 31.2 pg/ml to 2000 pg/ml. The chromogenic reaction was read at 415 nm (Molecular Devices).

**Light microscopy**
Collagen samples were processed according to a standard protocol. In short, they were fixed, dehydrated in increasing gradients of ethanol and embedded in paraffin. Thin sections were sliced, stained according to an azan standard procedure and fixed in methacrylate.

The sections were evaluated with a light microscope (Zeiss Axioscop, Jena, Germany).

**Scanning electron microscopy (SEM)**
Samples were fixed in 3% glutaraldehyde in 0.1 mol phosphate buffered saline and then washed in the buffer (0.1 mol PBS). After rinsing, the samples were dehydrated in a graded ethanol series and dried with a critical point drying. All dried samples were mounted on aluminium stubs and sputter coated with coal to a coating thickness of 8 nm.

For immunohistochemical SEM analysis the sections were fixed in 4% paraformaldehyde solution, rinsed with 0.1 mol PBS buffer and incubated with primary VEGF<sub>165</sub>-specific antibodies at room temperature for 1 hour. Afterwards, the secondary immunogold-labelled antibody was incubated at room temperature for 1 hour. Between incubation steps phosphate buffered saline rinses were performed. All antibodies were diluted according to the manufacturers’ instructions.

The gold particles as spheres of a 10 nm diameter were easily detectable in scanning electron microscopy.

**Transmission electron microscopy (TEM)**
For TEM analysis the collagen samples were fixed in 3% glutaraldehyde for 24 hours, rinsed in 0.1 mol phosphate buffered saline and incubated in osmium acid for 1 hour.

Afterwards, the samples were dehydrated in a graded ethanol series, embedded in araldite and sliced thin sections (1 μm). The slices were stained with toluidin blue following a standard procedure. Representative areas were cut in ultra-thin slices of 70 nm, placed on copper nets and analysed in transmission electron microscopy.

Immunohistochemical staining was performed as described before; the gold spheres in TEM presented as dark areas.

**Results**

**VEGF<sub>165</sub> half-life**
To determine biological half-life of VEGF<sub>165</sub> its dissolution in aqueous solution at room temperature was analysed. VEGF<sub>165</sub> collagen complexes charged with 10 μg of VEGF<sub>165</sub> were probed over 12 hours. Our results provide a half-life of free VEGF<sub>165</sub> of 90 minutes (Fig. 1).

**VEGF<sub>165</sub> release kinetics**
In a half-logarithmic presentation the observed VEGF<sub>165</sub> concentration showed a characteristic linear decline over time. The gradients of the three VEGF<sub>165</sub> doses were parallel and independent of VEGF<sub>165</sub> concentration. VEGF<sub>165</sub> release reached a plateau after 12 hours and was no longer detectable in the applications of 0.8 μg and 10 μg after 48 hours, whereas the complex charged with 80 μg of VEGF<sub>165</sub> still showed measurable cytokine release after over 50 hours. Saturation effects of the buffer medium were not observed (Fig. 2).

**VEGF<sub>165</sub> degradation**
The efficiency describes the quotient of VEGF<sub>165</sub> values scored in our test setting and initially applied VEGF<sub>165</sub>. Only 10% of initially applied 0.8 μg were finally detected in the present study. Ninety per cent were lost during production, transport or storage. Of the applied 10 μg and 80 μg, 96% respectively 97% were lost (Fig. 3).

![Figure 1 Half-life of VEGF.](image-url)
Light microscopy
In light microscopy the VEGF_{165} collagen complex appears homogenously, presents a reticular structure and shows no signs of structural defaults caused by fixation or coupling with VEGF_{165}. Only in the periphery single agglutinated fibres are detected; these are artefacts caused by the production process (Fig. 4).

SEM
In scanning electron microscopy the VEGF_{165} collagen complexes feature more agglutinated parts, even in central areas, in contrast to the collagen matrix without cytokine (Fig. 5a and 5b).

During the five days of degradation process the ultrastructure of the VEGF_{165} collagen complexes changes considerably. On day 0, the collagen matrix is coated by a VEGF_{165} layer that varnishes the single collagen fibrils. After 3 days of simulated circulation the collagen fibres are clearly detectable; this effect is more obvious on day five. The collagen matrix appears porose and knotty (Fig. 6a and 6b).

TEM
In transmission electron microscopy the gold particles present themselves as black round structures (Fig. 8). Single VEGF antibody complexes can be precisely assigned to their corresponding collagen fibril. Due to the close vicinity between fibre and VEGF an adhesion must be assumed that overcomes the preliminary chemical procedure for TEM (Fig. 9).

Discussion
To restore form and function to an existing bony defect, vascularisation is the key to success.

Clinical experience shows that avascular bony structures namely in chronically infected bones tend to atrophy and fracture [20].

Circulation and angiogenesis are responsible for a restored perfusion of impaired bone areas.

Bone cells on the other hand release growth factors to stimulate angiogenesis. Osteo- and angiogenesis are clearly linked in a strong co-dependent relation. The high susceptibility and the low applicable doses of cytokines
make high demands: next to good biocompatibility, an easy application mode is critical for the successful use of biomaterials for regenerative medicine strategies [21,22]. VEGF\textsubscript{165} has been exposed as the central angiogenetic protein in the process of bone regeneration; many in-vitro studies underlined its potency to stimulate osteogenesis physiologically via induction of neo-vascularisation [23]. Xenogenic collagen is a well established drug carrier in daily clinical use. As freeze-dried sponge it comes with excellent biocompatibility and is hence the ideal carrier for cytokine application.

In the present study the combination of a xenogenic collagen carrier and recombinant human VEGF\textsubscript{165} is analysed pharmacologically and morphologically. This kind of research is crucial for forthcoming in-vivo studies where biological factors will overlie and falsify the therapeutic effects of the VEGF\textsubscript{165} collagen complex. To be able to interpret these results properly drug release kinetics has to be established before. In cell cultures the VEGF\textsubscript{165} specific half-maximum growth stimulation has been determined. The effect of applied cytokines is supposed to range above this score [24].

Our data accounts for VEGF\textsubscript{165} release from the collagen over 48 hours; considering the 90 minutes half-life of free VEGF\textsubscript{165} it is a surprising result. Obviously, a stabilisation of VEGF\textsubscript{165} can be achieved by connecting the cytokine with collagen fibrils. The trial at hand provides only indirect evidence for this assumption but is observed in the whole test series.

During the first 50 hours an elevated release rate was observed as described in the literature before. The VEGF\textsubscript{165} release is divided in two phases: first, the quick elusion of VEGF\textsubscript{165} and diffusion into the buffer medium, and second, the slow sustained disposal when the VEGF\textsubscript{165} molecules are dissolved from the degrading collagen fibrils in the deeper areas of the matrix.

This pharmacological behaviour corresponds with our morphological findings in REM: hydrolytic erosion reveals the single collagen fibrils and facilitates VEGF\textsubscript{165} release.

The fraction of released VEGF\textsubscript{165} varies in our data from 3\% to 10\%. Despite ideal test condition the main
section of VEGF<sub>165</sub> is lost during production, transport and storage.

The decreasing efficacy of the higher concentrated VEGF<sub>165</sub> Carriers argues for a saturation effect, higher doses of VEGF<sub>165</sub> in the collagen scaffold do not lead to higher VEGF<sub>165</sub> release [6].

To sum up: The biphasic release kinetic allows a hyper-physiological stimulation caused by the applied VEGF<sub>165</sub> over 50 hours. It is more efficient than free VEGF<sub>165</sub>. Higher doses of VEGF<sub>165</sub> do not lead to better effects for there is no proportional connection between the dose in the collagen carrier and the emitted total quantity.

The next steps to elucidate the biological behaviour of the cytokine collagen complex are in-vitro trials to eliminate the shortcomings of our setting

- PBS as an inadequate model for blood flow in human tissues
- disregards enzymatic degradation processes
- insufficient verification of biologically active cytokine areas

The interfacing of VEGF<sub>165</sub> to a collagen scaffold is not the only way of cytokine application: its transport in micro spheres was described; cytokine mRNA was coupled with a viral vector and cytokine plasmid DNA was directly transferred into the tissue [25-27].

Conclusions
The restitution of bony defaults with a technique that provides biologic functionality, easy mechanical handling and reliable outcome is a significant challenge in maxillofacial surgery.

Our idea was to combine an osteoconductive scaffold with osteoinductive proteins and hence to stimulate and support natural healing and regenerating processes.

Our in-vitro trial substantiates the position of cytokine collagen complexes as innovative and effective treatment tools in regenerative medicine and paves the way for further clinical research.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
CF established the circulation model.
JK carried out the immunoassays.
SJ and KW participated in the design of the study and performed the statistical analysis.
UJ, JK and CF conceived of the study, and participated in its design and coordination and helped to draft the manuscript.
CF and UJ were involved in revising the article.
All authors read and approved the final manuscript.

Author Details
1Department of Cranio-Maxillofacial Surgery, Research Unit "Vascular Biology of Oral Structures (VABOS)", University Hospital Muenster, Waldeyerstrasse 30, D-48149, Muenster, Germany and 2Private practice, Duetmen, Germany

Received: 2 June 2010 Accepted: 19 July 2010
Published: 19 July 2010

References
1. Reddi A. Bone and cartilage differentiation. Curr Opin Gen Develop 1994, 4:273-274.
2. Caplan AI. Cartilage begets bone versus endochondral myeloepoiesis. Clin Orthop 1990, 261:257-267.
3. Kübler N. Osteoinduktion und -reparation. Mund Kiefer GesichtsChir 1997, 12:25.
4. Schmidt K, Siewboda H. Die Bedeutung matrixgebundener Zytokine für die Osteoinduktion und Osteogenese. Implantologie 1995, 2:127-148.
5. Sauter E, Nesbit M, Watson J, Klein-Santo A, Litwin S, Herlyn M. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 1999, 5:775-782.
6. Schlepheke H, Jamil M, Kriebel J. Experimental reconstruction of the mandible using polyactic acid tubes and basic fibroblast growth factor in alloplastic scaffolds. J Oral Maxillofac Surg 1998, 56:816-826.
7. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea K, Powell-Braxton L, Hillian K, Moore M. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439-443.
8. Kleinheinz J, Joos U. Serum concentration of VEGF and bFGF in patients with sagittal split ramus osteotomy. Int J Oral Maxillofac Surg 1999, 28:539.
9. Hollinger J, Wong M. The integrated process of hard tissue regeneration with special emphasis on fracture healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996, 82:594-606.
10. Mattei MG, Bong JP, Rosnet O, Marmel D, Bimbard M. Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12-p21 and 14q24-q31 regions, respectively. Genomics 1996, 32:168-9.
11. Drake CJ, Little CD. Exogenous vascular endothelial growth factor induces malformation and hyperperfused vessels during embryonic neovascularization. Proc Natl Acad Sci USA 1993, 90:7657-61.
12. Keck PJ, Hauser SD, Kripli G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989, 246:1309-12.
13. Plate KH, Breiger G, Risau W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 1994, 4:207-18.
14. Sengier DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993, 12:303-24.
15. Hutmacher D, Kirsch A, Ackermann K, Hürzeler M. Matrix and carrier for bone growth factors: state of the art and future perspectives. Berlin Heidelberg, Springer; 1998.
16. Wang D, Yamaizaki K, Nothmi A, Shizume K, Ohsumi K, Shibuya M, Sato K. Increase of vascular endothelial growth factor mRNA expression by 1,25-dihydroxyvitamin D3 in human osteoblast-like cells. J Bone Miner Res 1996, 11:472-479.
17. Ramselaar M, Driessen F, Kalk W, De Wijn J, Van Mullem P. Biodegradation of four calcium phosphate ceramics; in vivo rates and tissue interactions. J Mat Sci 1991, 263:70.
18. Hennrich A, Lehmann R, Khoury F, Schulte A, Hidding J. Filling cysts with type 1 bone collagen. Dtsch Zahnarztl Z 1989, 44:590-592.
19. Basle M, Lesourd M, Grizon F, Pascaretti C, Chappard D. Typ-I-Kollagen im xenogenen Knochenmaterial reguliert Anbindung und Verbreitung von Osteoplasten über die B1-Integrin-Untereinheit. Orthopäde 1998, 27:136-142.
20. Buchardt H. Biology of bone transplantation. Orthop Clin North Am 1987, 18:187-196.
21. Croteau G, Park T. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. J Microencapsulation 1998, 15:699-713.
22. Arnold F, West D. Angiogenesis in wound healing. Pharm Ther 1991, 2:407-422.
23. Iuel-Arispe M, Dvorak H. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thrombosis and Haemostasis 1997, 78:672-677.
24. Kremer C, Breier G, Risau W, Plate KH: Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. *Cancer Res* 1997, 57:3852-9.

25. Safi J, DiPaula A, Riccioni T, Kajstura J, Ambrosio G, Becker L, Anversa P, Capogrossi M: Adenovirus-mediated acidic fibroblast growth factor gene transfer induces angiogenesis in the nonischemic rabbit heart. *Microvasc Res* 1999, 58:238-249.

26. Franceschi RT: Biological approaches to bone regeneration by gene therapy. *J Dent Res* 2005, 84:1093-103.

27. Isner J, Pieczek A, Schanefeld R, Blair R, Haley L, Asahara T, Rosenfield K, Razvi S, Wash K, Symes J: Clinical evidence of angiogenesis after gene transfer of phVEGF165 in patient with ischemic limb. *Lancet* 1996, 348:370-374.

doi: 10.1186/1746-160X-6-17

Cite this article as: Kleinheinz et al., Release kinetics of VEGF165 from a collagen matrix and structural matrix changes in a circulation model *Head & Face Medicine* 2010, 6:17